Tag: Cell

  • Ancient genomes unearth degenerate transposable elements in human DNA

    Ancient genomes unearth degenerate transposable elements in human DNA

    [ad_1]

    The human genome, an intricate tapestry of genetic information for life, has proven to be a treasure trove of strange features. Among them are segments of DNA that can “jump around” and move within the genome, known as “transposable elements” (TEs).

    As they change their position within the genome, TEs can potentially cause mutations and alter the cell’s genetic profile, but also are master orchestrators of our genome’s organization and expression. For example, TEs contribute to regulatory elements, transcription factor binding sites, and the creation of chimeric transcripts – genetic sequences created when segments from two different genes or parts of the genome join together to form a new, hybrid RNA molecule.

    Matching their functional importance, TEs have been recognized to account for half of the human DNA. However, as they move and age, TEs pick up changes that mask their original form. Over time, TEs “degenerate” and become less recognizable, making it difficult for scientists to identify and track them in our genetic blueprint.

    In a new study, researchers in the group of Didier Trono at EPFL have found a way to improve the detection of TEs in the human genome by using reconstructed ancestral genomes from various species, which allowed them to identify previously undetectable degenerate TEs in the human genome. The study is published in Cell Genomics.

    The scientists used a database of reconstructed ancestral genomes from different kinds of species, like a genomic “time machine”. By comparing the human genome with the reconstructed ancestral genomes, they could identify TEs in the latter that, over millions of years, have become degenerate (worn out) in humans.

    This comparison allowed them to detect (“annotate”) TEs that might have been missed in previous studies that used data only from the human genome.

    Using this approach, the scientists uncovered a larger number of TEs than previously known, adding significantly to the share of our DNA that is contributed by TEs. Furthermore, they could demonstrate that these newly unearthed TE sequences played all the same regulatory roles as their more recent, already identified relatives.

    The potential applications are vast. 

    Better understanding TEs and their regulators could lead to insights into human diseases, many of which are believed to be influenced by genetic factors. First and foremost, cancer, but also auto-immune and metabolic disorders, and more generally our body’s response to environmental stresses and aging.”


    Didier Trono at EPFL

    Source:

    Journal reference:

    Matsushima, W., et al. (2024). Ancestral genome reconstruction enhances transposable element annotation by identifying degenerate integrants. Cell Genomics. doi.org/10.1016/j.xgen.2024.100497.

    [ad_2]

    Source link

  • XRCC1 shows potential as a prognostic and immunological pan-cancer biomarker

    XRCC1 shows potential as a prognostic and immunological pan-cancer biomarker

    [ad_1]

    A new research paper was published in Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science) Volume 16, Issue 1, entitled, “XRCC1: a potential prognostic and immunological biomarker in LGG based on systematic pan-cancer analysis.”

    X-ray repair cross-complementation group 1 (XRCC1) is a pivotal contributor to base excision repair, and its dysregulation has been implicated in the oncogenicity of various human malignancies. However, a comprehensive pan-cancer analysis investigating the prognostic value, immunological functions, and epigenetic associations of XRCC1 remains lacking.

    In this new study, researchers Guobing Wang, Yunyue Li, Rui Pan, Xisheng Yin, Congchao Jia, Yuchen She, Luling Huang, Guanhu Yang, Hao Chi, and Gang Tian from Southwest Medical University, The Affiliated Hospital of Southwest Medical University, Yibin Hospital of T.C.M, Medical School of Nanchang University, Fourth Military Medical University, and Ohio University aimed to address this knowledge gap by conducting a systematic investigation employing bioinformatics techniques across 33 cancer types.

    “Our analysis encompassed XRCC1 expression levels, prognostic and diagnostic implications, epigenetic profiles, immune and molecular subtypes, Tumor Mutation Burden (TMB), Microsatellite Instability (MSI), immune checkpoints, and immune infiltration, leveraging data from TCGA, GTEx, CELL, Human Protein Atlas, Ualcan, and cBioPortal databases.”

    Notably, XRCC1 displayed both positive and negative correlations with prognosis across different tumors. Epigenetic analysis revealed associations between XRCC1 expression and DNA methylation patterns in 10 cancer types, as well as enhanced phosphorylation. Furthermore, XRCC1 expression demonstrated associations with TMB and MSI in the majority of tumors. 

    Interestingly, XRCC1 gene expression exhibited a negative correlation with immune cell infiltration levels, except for a positive correlation with M1 and M2 macrophages and monocytes in most cancers. Additionally, the researchers observed significant correlations between XRCC1 and immune checkpoint gene expression levels. Lastly, their findings implicated XRCC1 in DNA replication and repair processes, shedding light on the precise mechanisms underlying its oncogenic effects. 

    “Overall, our study highlights the potential of XRCC1 as a prognostic and immunological pan-cancer biomarker, thereby offering a novel target for tumor immunotherapy.”

    Source:

    Journal reference:

    Wang, G., et al. (2024). XRCC1: a potential prognostic and immunological biomarker in LGG based on systematic pan-cancer analysis. Aging. doi.org/10.18632/aging.205426.

    [ad_2]

    Source link

  • Study unmasks secrets of glioma’s invasive margins

    Study unmasks secrets of glioma’s invasive margins

    [ad_1]

    High-grade gliomas are cancerous tumors that spread quickly in the brain or spinal cord. In a new study led by Mayo Clinic, researchers found invasive brain tumor margins of high-grade glioma (HGG) contain biologically distinct genetic and molecular alterations that point to aggressive behavior and disease recurrence. The findings suggest insights into potential treatments that could modify the course of the disease.

    The study published in Nature Communications, profiled 313 tumor biopsies from 68 HGG patients using genomics (study of genes), transcriptomics (study of gene expression at the mRNA level) and magnetic resonance imaging (MRI).

    Glioma is a growth of cells that starts in the brain or spinal cord. The invasive margins of HGG have long remained a mystery due to the difficulties in surgical biopsy of these regions. The aggressive nature of most gliomas, and the visual and textural similarities between the affected regions and normal tissue, create a challenge for neurosurgeons during removal of the tumor. Some glioma cells may get left behind.

    The cells in a glioma look like healthy brain cells called glial cells. As a glioma grows, it forms a mass of cells called a tumor. The tumor can grow to press on brain or spinal cord tissue, causing a range of symptoms. There are many types of glioma. Some grow slowly and aren’t considered to be cancers. Others are considered cancerous. Malignant gliomas grow quickly and can invade healthy brain tissue.

    Leland Hu, M.D., a neuroradiologist at Mayo Clinic in Arizona, says the study also shows that MRI techniques, such as dynamic susceptibility contrast and diffusion tensor imaging, can help distinguish between the genetic and molecular alterations of invasive tumors, which is important for clinically characterizing areas that are difficult to surgically biopsy.

    “We need to understand what is driving tumor progression,” says Dr. Hu. “Our results demonstrate an expanded role of advanced MRI for clinical decision-making for high-grade glioma.”

    The study also provides insight into resistance to treatment that could improve future outcomes.

    Our hope is that these clinical MRI techniques will lead to improved diagnosis, prognosis and treatment. We are looking at this research through the lens of therapeutic decision-making for patients.”


    Nhan Tran, Ph.D., cancer biologist, Department of Cancer Biology at Mayo Clinic, Arizona

    The entire dataset, including genomics, transcriptomics and MRI, is publicly available to other groups and institutions as a resource to fuel new discoveries beyond what Dr. Hu and colleagues have reported in the initial manuscript.

    Sources:

    Journal reference:

    Hu, L. S., et al. (2023). Integrated molecular and multiparametric MRI mapping of high-grade glioma identifies regional biologic signatures. Nature Communications. doi.org/10.1038/s41467-023-41559-1.

    [ad_2]

    Source link